Clare Sun

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1676245/publications.pdf

Version: 2024-02-01

56 papers	1,854 citations	361045 20 h-index	264894 42 g-index
56 all docs	56 docs citations	56 times ranked	2791 citing authors

#	Article	IF	Citations
1	Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood, 2015, 126, 2213-2219.	0.6	198
2	Disruption of in vivo Chronic Lymphocytic Leukemia Tumorâ€“Microenvironment Interactions by Ibrutinib â€“ Findings from an Investigator-Initiated Phase II Study. Clinical Cancer Research, 2016, 22, 1572-1582.	3.2	168
3	Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. Blood, 2018, 131, 2357-2366.	0.6	166
4	The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. Nature Communications, 2017, 8, 2185.	5.8	148
5	Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica, 2015, 100, 1571-1578.	1.7	137
6	Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines. Blood, 2021, 137, 185-189.	0.6	110
7	Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood. Leukemia, 2017, 31, 1340-1347.	3.3	103
8	Anal fistula plug and fibrin glue versus conventional treatment in repair of complex anal fistulas. American Journal of Surgery, 2009, 197, 604-608.	0.9	82
9	A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era. Blood, 2018, 132, 521-532.	0.6	81
10	Seasonal Influenza Vaccination in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib. JAMA Oncology, 2016, 2, 1656.	3.4	75
11	Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib. Blood, 2020, 136, 93-105.	0.6	68
12	Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia. Haematologica, 2017, 102, 874-882.	1.7	67
13	Outcomes of anal fistula surgery in patients with inflammatory bowel disease. American Journal of Surgery, 2010, 199, 609-613.	0.9	46
14	Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL. International Journal of Molecular Sciences, 2020, 21, 68.	1.8	34
15	Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia. Leukemia, 2017, 31, 340-349.	3.3	33
16	Overcoming Acquired Epigenetic Resistance to BTK Inhibitors. Blood Cancer Discovery, 2021, 2, 630-647.	2.6	30
17	Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia. Leukemia and Lymphoma, 2018, 59, 2792-2800.	0.6	28
18	Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. Leukemia, 2021, 35, 3201-3211.	3.3	25

#	Article	IF	Citations
19	p27kip1 maintains a subset of leukemia stem cells in the quiescent state in murine MLLâ€leukemia. Molecular Oncology, 2013, 7, 1069-1082.	2.1	23
20	Activation of Th1 Immunity within the Tumor Microenvironment Is Associated with Clinical Response to Lenalidomide in Chronic Lymphocytic Leukemia. Journal of Immunology, 2018, 201, 1967-1974.	0.4	22
21	Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib. Clinical Cancer Research, 2020, 26, 2800-2809.	3.2	18
22	COVID-19 vaccines for patients with haematological conditions. Lancet Haematology,the, 2021, 8, e312-e314.	2.2	18
23	BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL. Blood, 2021, 138, 1843-1854.	0.6	17
24	IKAPâ€"Identifying K mAjor cell Population groups in single-cell RNA-sequencing analysis. GigaScience, 2019, 8, .	3.3	16
25	Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors. Leukemia and Lymphoma, 2020, 61, 2375-2382.	0.6	16
26	The immune microenvironment shapes transcriptional and genetic heterogeneity in chronic lymphocytic leukemia. Blood Advances, 2023, 7, 145-158.	2.5	15
27	MARCKS affects cell motility and response to BTK inhibitors in CLL. Blood, 2021, 138, 544-556.	0.6	14
28	BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL. Blood Advances, 2022, 6, 1732-1740.	2.5	13
29	Prognosis and Therapy of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. Cancer Treatment and Research, 2015, 165, 147-175.	0.2	11
30	Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: â€œWhat's Past Is Prologueâ€• (Shakespeare). Clinical Cancer Research, 2022, 28, 603-608.	3.2	11
31	Select Antitumor Cytotoxic CD8+ T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. Clinical Cancer Research, 2021, 27, 4624-4633.	3.2	10
32	Activation of Notch and Myc Signaling via B-cellâ€"Restricted Depletion of Dnmt3a Generates a Consistent Murine Model of Chronic Lymphocytic Leukemia. Cancer Research, 2021, 81, 6117-6130.	0.4	10
33	Response to the Shingrix Varicella Zoster Virus (VZV) Vaccine in Patients with Chronic Lymphocytic Leukemia (CLL) That Are Treatment Naive or Treated with a Bruton's Tyrosine Kinase Inhibitor (BTK-I). Blood, 2019, 134, 3053-3053.	0.6	5
34	Polyreactive antibodies in CLL correlate with the level of immunoglobulins not the number of B lymphocytes. Leukemia and Lymphoma, 2019, 60, 242-245.	0.6	4
35	Pooled Analysis of Cardiovascular Events from Clinical Trials Evaluating Acalabrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2020, 136, 52-54.	0.6	4
36	Richter transformation to Hodgkin lymphoma on Brutonâ€™s tyrosine kinase inhibitor therapy. Leukemia and Lymphoma, 2019, 60, 519-522.	0.6	3

#	Article	IF	Citations
37	A phase <scp>II</scp> study of ibrutinib and shortâ€course fludarabine in previously untreated patients with chronic lymphocytic leukemia. American Journal of Hematology, 2020, 95, E310-E313.	2.0	3
38	Can Immunocompetence Be Restored in Chronic Lymphocytic Leukemia?. Hematology/Oncology Clinics of North America, 2021, 35, 827-845.	0.9	3
39	The Landscape of Dynamic Genetic Changes in Ibrutinib-Treated CLL. Blood, 2016, 128, 188-188.	0.6	3
40	Dynamic Alterations in Gene Expression in Ibrutinib Treated CLL Reveal Profound Impact on Multiple Signaling Pathways. Blood, 2016, 128, 189-189.	0.6	3
41	COVID â€19 vaccine response in chronic lymphocytic leukaemia is more than just seroconversion. British Journal of Haematology, 2022, , .	1.2	3
42	Protracted course of disseminated adenovirus disease with necrotizing granulomas in the liver. Diagnostic Microbiology and Infectious Disease, 2019, 94, 180-182.	0.8	2
43	CLL kinetics in the tumor microenvironment. Oncotarget, 2017, 8, 84634-84634.	0.8	2
44	A CD19/CD3 Bispecific Antibody Induces Superior T Cell Responses Against Chronic Lymphocytic Leukemia When Combined with Ibrutinib. Blood, 2019, 134, 2861-2861.	0.6	2
45	Under the microscope: CCL3 and T cells in the microenvironment of chronic lymphocytic leukemia. Leukemia and Lymphoma, 2016, 57, 501-502.	0.6	1
46	Ibrutinib Inhibits Both B-Cell Receptor and Toll-like Receptor Signaling in Chronic Lymphocytic Leukemia. Blood, 2015, 126, 313-313.	0.6	1
47	Lymphocyte Activation Gene 3-a Novel Therapeutic Target in Chronic Lymphocytic Leukemia. Blood, 2016, 128, 2018-2018.	0.6	1
48	Diverging Clonal Evolution during Sequential Therapy with Chemoimmunotherapy Followed By BTK Inhibitors. Blood, 2019, 134, 850-850.	0.6	1
49	Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naÃ¯ve chronic lymphocytic leukemia: a phase 2 study. Leukemia and Lymphoma, 2021, 62, 1816-1827.	0.6	0
50	Intensity of antigen expression reflects IGHV mutational status and Dohner-defined prognostic categories in chronic lymphocytic leukemia, monoclonal B-cell lymphocytosis, and small lymphocytic lymphoma. Leukemia and Lymphoma, 2021, 62, 1828-1839.	0.6	0
51	Focal Adhesion Kinase Inactivation Reduces the Development of Acute Leukemia and Partially Rescues Hematopoietic Stem Cell Defects in Pten-Knockout Mice. Blood, 2012, 120, 864-864.	0.6	0
52	FLT3 Signaling Enhances Stemness in Murine MLL-AF9 Acute Myeloid Leukemia.. Blood, 2012, 120, 2980-2980.	0.6	0
53	Ibrutinib Responsive Micro-RNAs and Upregulation of Tumor Suppressor Targets in Chronic Lymphocytic Leukemia. Blood, 2015, 126, 487-487.	0.6	0
54	Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib Show Expansion of T-Cell Clonotypes Composed of Antitumor Cytotoxic CD8+ T-Cells. Blood, 2019, 134, 3030-3030.	0.6	0

#	Article	IF	Citations
55	Spatial Genomic Heterogeneity in Chronic Lymphocytic Leukemia. Blood, 2019, 134, 3017-3017.	0.6	0
56	Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia. Blood, 2019, 134, 3052-3052.	0.6	0